Adjuvant Therapy for Renal Cell Carcinoma
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy for renal cell carcinoma (RCC).
Sumanta Kumar Pal, MD, assistant professor, genitourinary cancers, City of Hope, discusses adjuvant therapy for renal cell carcinoma (RCC).
Clinical Pearls:
- Adjuvant therapy is not currently a standard of care for localized RCC, however there are several studies that could put these agents into that disease space
- These studies are looking at VEGF- and mTOR-directed therapies
- Results of the ASSURE trial, which compared sunitinib, sorafenib and placebo in the adjuvant setting, will hopefully report out within the next 2-3 years
- Patients in the adjuvant setting may not tolerate the same doses as in the metastatic setting
- The EVEREST trial, which compares everolimus to placebo in the adjuvant setting, is about halfway accrued.
- Girentuximab, which targets CA9, was found to not have a significant impact on disease-free survival or overall survival
Enhancing Precision in Immunotherapy: CD8 PET-Avidity in RCC
March 1st 2024In this episode of Emerging Experts, Peter Zang, MD, highlights research on baseline CD8 lymph node avidity with 89-Zr-crefmirlimab for the treatment of patients with metastatic renal cell carcinoma and response to immunotherapy.
Listen
Beyond the First-Line: Economides on Advancing Therapies in RCC
February 1st 2024In our 4th episode of Emerging Experts, Minas P. Economides, MD, unveils the challenges and opportunities for renal cell carcinoma treatment, focusing on the lack of therapies available in the second-line setting.
Listen
